Catheter Precision to Attend Society for Cardiac Robotic Navigation With New Clinical Data Presented on October 28 – 29
Catheter Precision (NYSE American:VTAK) announced two presentations featuring their VIVO technology at the International Society for Cardiac Robotic Navigation Meeting in Lisbon, Portugal, October 28-29. Dr. Jack Griffiths from Royal Brompton Hospital will present on 'Robotics in VT plus non-invasive 3D mapping', focusing on time-saving data. Peter van Dam, PhD will discuss 'Non-invasive Mapping Using Individual Anatomy', highlighting VIVO's patient-specific advantages. Dr. Leonor Perriera will present updates from the VIVO European Registry, including acute success and 12-month follow-up data for ventricular ablation.
Catheter Precision (NYSE American:VTAK) ha annunciato due presentazioni riguardanti la loro tecnologia VIVO presso l'International Society for Cardiac Robotic Navigation Meeting a Lisbona, Portogallo, il 28-29 ottobre. Il Dr. Jack Griffiths dell'Ospedale Royal Brompton presenterà su 'Robotica in VT e mappatura 3D non invasiva', con un focus sui dati che fanno risparmiare tempo. Il Dr. Peter van Dam discuterà 'Mappatura non invasiva utilizzando anatomia individuale', evidenziando i vantaggi specifici per i pazienti offerti da VIVO. La Dr.ssa Leonor Perriera fornirà aggiornamenti dal Registro Europeo VIVO, compresi i dati di successo acuto e follow-up a 12 mesi per l'ablazione ventricolare.
Catheter Precision (NYSE American:VTAK) anunció dos presentaciones sobre su tecnología VIVO en la Reunión de la Sociedad Internacional de Navegación Robótica Cardíaca en Lisboa, Portugal, del 28 al 29 de octubre. El Dr. Jack Griffiths del Hospital Royal Brompton.presentará sobre 'Robótica en VT y mapeo 3D no invasivo', enfocándose en datos que ahorran tiempo. El Dr. Peter van Dam discutirá 'Mapeo no invasivo utilizando anatomía individual', destacando las ventajas específicas para el paciente de VIVO. La Dra. Leonor Perriera presentará actualizaciones del Registro Europeo VIVO, incluidos los datos de éxito agudo y seguimiento a 12 meses para la ablación ventricular.
Catheter Precision(NYSE American:VTAK)는 10월 28일과 29일 포르투갈 리스본에서 열린 국제 심장 로봇 내비게이션 회의에서 VIVO 기술과 관련된 두 개의 발표를 발표했습니다. 잭 그리피스 박사는 로열 브롬턴 병원 소속으로 'VT 및 비침습적 3D 맵핑에서의 로봇 공학'에 대해 발표하며 시간 절약 데이터를 강조할 것입니다. 피터 반 담 박사는 '개별 해부학을 이용한 비침습적 맵핑'에 대해 논의하고 VIVO의 환자 특화 장점을 강조할 것입니다. 레오노르 페리레라 박사는 VIVO 유럽 등록부의 최신 정보를 제공하며, 심실 절제술에 대한 급성 성공 및 12개월 추적 데이터가 포함됩니다.
Catheter Precision (NYSE American:VTAK) a annoncé deux présentations concernant leur technologie VIVO lors de la Réunion de la Société Internationale de Navigation Robotique Cardiaque qui se tiendra à Lisbonne, Portugal, les 28 et 29 octobre. Le Dr Jack Griffiths de l'Hôpital Royal Brompton présentera sur 'Robotique dans la VT et cartographie 3D non invasive', en se concentrant sur des données permettant de gagner du temps. Peter van Dam, PhD discutera de 'Cartographie non invasive utilisant l'anatomie individuelle', mettant en avant les avantages spécifiques pour les patients offerts par VIVO. Le Dr Leonor Perriera présentera des mises à jour du Registre Européen VIVO, y compris des données sur le succès aigu et le suivi à 12 mois pour l'ablation ventriculaire.
Catheter Precision (NYSE American:VTAK) gab bekannt, dass sie zwei Präsentationen über ihre VIVO-Technologie beim International Society for Cardiac Robotic Navigation Meeting in Lissabon, Portugal, am 28. und 29. Oktober halten werden. Dr. Jack Griffiths vom Royal Brompton Hospital wird über 'Robotik in VT und nicht-invasive 3D-Karten' sprechen und sich auf zeitersparende Daten konzentrieren. Peter van Dam, PhD wird 'Nicht-invasive Kartierung unter Verwendung individueller Anatomie' diskutieren und die patientenspezifischen Vorteile von VIVO hervorheben. Dr. Leonor Perriera wird Updates aus dem VIVO Europäischen Register vorstellen, einschließlich akuter Erfolgs- und 12-Monats-Nachfolgedaten zur ventrikulären Ablation.
- Clinical data from VIVO European Registry to be presented, including acute success and 12-month follow-up results
- Previously published data shows time-saving benefits of VIVO technology
- VIVO's patient-specific approach offers advantages over competing non-invasive mapping systems
- None.
FORT MILL, SC / ACCESSWIRE / October 23, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products announced that there will be two presentations showcasing the VIVO technology at the International Society for Cardiac Robotic Navigation Meeting (SCRN) October 28-29 in Lisbon, Portugal.
The 2024 program highlights VIVO in the presentations. The first is October 28 and is titled "Robotics in VT plus non-invasive 3D mapping" by Dr. Jack Griffiths from the Royal Brompton Hospital in London. This presentation will focus on his experience with VIVO to include his previously published data about time savings.
The second presentation is by Peter van Dam, PhD on October 29 and is titled "Non-invasive Mapping Using Individual Anatomy". Peter is the original engineer supporting the development of VIVO and will be presenting about the benefits of VIVO, which uses patient specific inputs, over other non-invasive mapping systems that do not. The third presentation, also on October 29, is presented by Dr. Leonor Perriera where she will provide update on the VIVO European Registry which has recently concluded. The data will include acute success and success at 12 month follow-up of the ventricular ablation.
"This year we have updated our corporate strategy to include not only new, but more presentations during conferences", said David Jenkins, CEO of Catheter Precision. "Symposiums and conferences allow our sales team to have one-on-one time with physicians, but it also allows peer-to-peer interaction and discussion about emerging technologies and new clinical data. Supporting research that physicians can then present at conferences allows for the continued exchange of knowledge about Catheter Precision's products and how those products can improve procedural efficiency and more importantly, patient outcomes."
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
VIVO Indications for Use (USA)
VIVO is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.
VIVO is intended to be used as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation treatment for idiopathic ventricular arrhythmias.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
Contact Information
Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000
SOURCE: Catheter Precision
View the original press release on accesswire.com
FAQ
What clinical data will be presented for VTAK's VIVO technology at SCRN 2024?
When and where will Catheter Precision (VTAK) present at the SCRN meeting?
What are the advantages of VTAK's VIVO technology over other mapping systems?
